Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.
Identifieur interne : 000673 ( PubMed/Curation ); précédent : 000672; suivant : 000674Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.
Auteurs : Tetsuya Uchida [Japon]Source :
- Microbiology and immunology [ 0385-5600 ] ; 2011.
Descripteurs français
- KwdFr :
- MESH :
- administration et posologie : Liposomes.
- immunologie : Lymphocytes T cytotoxiques, Vaccins antigrippaux.
- physiologie : Cellules présentatrices d'antigène.
- Animaux, Déterminants antigéniques des lymphocytes T, Grippe humaine, Humains, Mémoire immunologique.
English descriptors
- KwdEn :
- MESH :
- chemical , administration & dosage : Liposomes.
- chemical , immunology : Influenza Vaccines.
- chemical : Epitopes, T-Lymphocyte.
- immunology : T-Lymphocytes, Cytotoxic.
- physiology : Antigen-Presenting Cells.
- prevention & control : Influenza, Human.
- Animals, Humans, Immunologic Memory.
Abstract
The current vaccination strategy against influenza is to induce production of antibodies directed against the surface antigens of these viruses. However, frequent changes in the surface antigens of influenza viruses allow them to avoid antibody-mediated immunity. On the other hand, it is known that cytotoxic T-lymphocyte (CTL) populations directed against internal antigens of influenza A virus are broadly cross-reactive to influenza virus subtypes. The present authors have previously demonstrated that antigens chemically coupled to the surface of liposomes made using unsaturated fatty acids are cross-presented by APCs via MHC class I to CD8(+) T cells and induce antigen-specific CTLs. Based on this finding, a liposome vaccine that is capable of inducing CTL response against internal antigens of influenza viruses and removing virus-infected cells in the host has been developed. The CTL-based liposomal technique might be applicable for developing vaccines against influenza and other viruses, such as hepatitis C, HIV, and severe acute respiratory syndrome corona virus, which frequently change their surface antigenic molecules.
DOI: 10.1111/j.1348-0421.2010.00273.x
PubMed: 21175770
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000673
Links to Exploration step
pubmed:21175770Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.</title><author><name sortKey="Uchida, Tetsuya" sort="Uchida, Tetsuya" uniqKey="Uchida T" first="Tetsuya" last="Uchida">Tetsuya Uchida</name><affiliation wicri:level="1"><nlm:affiliation>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama-City, Tokyo, Japan. tuchida@nih.go.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama-City, Tokyo</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:21175770</idno><idno type="pmid">21175770</idno><idno type="doi">10.1111/j.1348-0421.2010.00273.x</idno><idno type="wicri:Area/PubMed/Corpus">000673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000673</idno><idno type="wicri:Area/PubMed/Curation">000673</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000673</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.</title><author><name sortKey="Uchida, Tetsuya" sort="Uchida, Tetsuya" uniqKey="Uchida T" first="Tetsuya" last="Uchida">Tetsuya Uchida</name><affiliation wicri:level="1"><nlm:affiliation>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama-City, Tokyo, Japan. tuchida@nih.go.jp</nlm:affiliation><country xml:lang="fr">Japon</country><wicri:regionArea>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama-City, Tokyo</wicri:regionArea></affiliation></author></analytic><series><title level="j">Microbiology and immunology</title><idno type="ISSN">0385-5600</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antigen-Presenting Cells (physiology)</term><term>Epitopes, T-Lymphocyte</term><term>Humans</term><term>Immunologic Memory</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Liposomes (administration & dosage)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Cellules présentatrices d'antigène (physiologie)</term><term>Déterminants antigéniques des lymphocytes T</term><term>Grippe humaine ()</term><term>Humains</term><term>Liposomes (administration et posologie)</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Mémoire immunologique</term><term>Vaccins antigrippaux (immunologie)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Liposomes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" xml:lang="en"><term>Epitopes, T-Lymphocyte</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Liposomes</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T cytotoxiques</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Cellules présentatrices d'antigène</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Antigen-Presenting Cells</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Immunologic Memory</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Déterminants antigéniques des lymphocytes T</term><term>Grippe humaine</term><term>Humains</term><term>Mémoire immunologique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The current vaccination strategy against influenza is to induce production of antibodies directed against the surface antigens of these viruses. However, frequent changes in the surface antigens of influenza viruses allow them to avoid antibody-mediated immunity. On the other hand, it is known that cytotoxic T-lymphocyte (CTL) populations directed against internal antigens of influenza A virus are broadly cross-reactive to influenza virus subtypes. The present authors have previously demonstrated that antigens chemically coupled to the surface of liposomes made using unsaturated fatty acids are cross-presented by APCs via MHC class I to CD8(+) T cells and induce antigen-specific CTLs. Based on this finding, a liposome vaccine that is capable of inducing CTL response against internal antigens of influenza viruses and removing virus-infected cells in the host has been developed. The CTL-based liposomal technique might be applicable for developing vaccines against influenza and other viruses, such as hepatitis C, HIV, and severe acute respiratory syndrome corona virus, which frequently change their surface antigenic molecules.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21175770</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>12</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0385-5600</ISSN><JournalIssue CitedMedium="Print"><Volume>55</Volume><Issue>1</Issue><PubDate><Year>2011</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Microbiology and immunology</Title><ISOAbbreviation>Microbiol. Immunol.</ISOAbbreviation></Journal><ArticleTitle>Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.</ArticleTitle><Pagination><MedlinePgn>19-27</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/j.1348-0421.2010.00273.x</ELocationID><Abstract><AbstractText>The current vaccination strategy against influenza is to induce production of antibodies directed against the surface antigens of these viruses. However, frequent changes in the surface antigens of influenza viruses allow them to avoid antibody-mediated immunity. On the other hand, it is known that cytotoxic T-lymphocyte (CTL) populations directed against internal antigens of influenza A virus are broadly cross-reactive to influenza virus subtypes. The present authors have previously demonstrated that antigens chemically coupled to the surface of liposomes made using unsaturated fatty acids are cross-presented by APCs via MHC class I to CD8(+) T cells and induce antigen-specific CTLs. Based on this finding, a liposome vaccine that is capable of inducing CTL response against internal antigens of influenza viruses and removing virus-infected cells in the host has been developed. The CTL-based liposomal technique might be applicable for developing vaccines against influenza and other viruses, such as hepatitis C, HIV, and severe acute respiratory syndrome corona virus, which frequently change their surface antigenic molecules.</AbstractText><CopyrightInformation>© 2010 The Societies and Blackwell Publishing Asia Pty Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Uchida</LastName><ForeName>Tetsuya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Safety Research on Blood and Biological Products, National Institute of Infectious Diseases, Musashimurayama-City, Tokyo, Japan. tuchida@nih.go.jp</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Australia</Country><MedlineTA>Microbiol Immunol</MedlineTA><NlmUniqueID>7703966</NlmUniqueID><ISSNLinking>0385-5600</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018984">Epitopes, T-Lymphocyte</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008081">Liposomes</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000938" MajorTopicYN="N">Antigen-Presenting Cells</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018984" MajorTopicYN="N">Epitopes, T-Lymphocyte</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007156" MajorTopicYN="N">Immunologic Memory</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008081" MajorTopicYN="N">Liposomes</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21175770</ArticleId><ArticleId IdType="doi">10.1111/j.1348-0421.2010.00273.x</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/CovidV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000673 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 000673 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= CovidV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:21175770
|texte= Development of a cytotoxic T-lymphocyte-based, broadly protective influenza vaccine.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:21175770" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a CovidV1
| This area was generated with Dilib version V0.6.33. |  |